Research Paper Volume 12, Issue 22 pp 22975—23003

Silencing KIF14 reverses acquired resistance to sorafenib in hepatocellular carcinoma

Figure 7. KIF14 silencing synergizes with sorafenib to suppress subcutaneous tumors formed from sorafenib-resistant cells in vivo. (A) Subcutaneous tumors were established in mice that received different treatments for 15 days as described in the Materials and Methods section. The volume (mm3) of tumors was recorded. (B and C) Tumors harvested at the end of experiments were weighed (B) and photographed (C). (D) Representative images of tumor sections stained with anti-Ki-67 Ab (top) and subjected to TUNEL assay (bottom; magnification, ×200). (E) The proliferation index (%) and (F) apoptosis index (%) were quantified. (G and H) Western blotting of lysates of tumors harvested from (A) at the end of experiments (G). The density of each band was normalized to that of β-actin (H). Scale bar = 500 μm. “*” Indicates P<0.05 and “**” indicates P<0.001.